BioTuesdays

Vital Therapies names Faheem Hasnain as a director

Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.

Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by Celgene for $7.8-billion. He is currently chairman of Tocagen and Sente.

“Faheem’s strong track record in biotechnology drug development will be extremely valuable as we continue executing on our current Phase 3 trial, VTL-308,” Muneer Satter, co-chairman, said in a statement.

Mr. Hasnain said he believes ELAD is a promising therapy addressing an important unmet need and looks forward to helping guide its development and potential commercialization.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.